非布司他在高尿酸血症患者中的使用和安全性

Q2 Medicine

The Journal of rheumatology. Supplement Pub Date : 2022-06-15 DOI:10.3899/jrheum.220147

T. Kawada

{"title":"非布司他在高尿酸血症患者中的使用和安全性","authors":"T. Kawada","doi":"10.3899/jrheum.220147","DOIUrl":null,"url":null,"abstract":"I read the paper by Deng et al,1 in which the authors conducted a metaanalysis to evaluate whether febuxostat use increased the risk of developing cardiovascular (CV) events, cardiac death, and all-cause mortality. The adjusted relative risk (RR) of febuxostat use for all-cause mortality was 0.87 (95% CI 0.57-1.32).","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Febuxostat Use and Safety in Patients With Hyperuricemia\",\"authors\":\"T. Kawada\",\"doi\":\"10.3899/jrheum.220147\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"I read the paper by Deng et al,1 in which the authors conducted a metaanalysis to evaluate whether febuxostat use increased the risk of developing cardiovascular (CV) events, cardiac death, and all-cause mortality. The adjusted relative risk (RR) of febuxostat use for all-cause mortality was 0.87 (95% CI 0.57-1.32).\",\"PeriodicalId\":35278,\"journal\":{\"name\":\"The Journal of rheumatology. Supplement\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-06-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Journal of rheumatology. Supplement\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3899/jrheum.220147\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of rheumatology. Supplement","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3899/jrheum.220147","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

我阅读了Deng等人的论文，其中作者进行了一项荟萃分析，以评估非布司他是否会增加发生心血管事件、心源性死亡和全因死亡率的风险。非布司他对全因死亡率的校正相对危险度(RR)为0.87 (95% CI 0.57-1.32)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Febuxostat Use and Safety in Patients With Hyperuricemia

I read the paper by Deng et al,1 in which the authors conducted a metaanalysis to evaluate whether febuxostat use increased the risk of developing cardiovascular (CV) events, cardiac death, and all-cause mortality. The adjusted relative risk (RR) of febuxostat use for all-cause mortality was 0.87 (95% CI 0.57-1.32).

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

The Journal of rheumatology. Supplement Medicine-Medicine (all)

自引率

0.00%

发文量

期刊介绍： The Journal of Rheumatology is a monthly international serial edited by Duncan A. Gordon, The Journal features research articles on clinical subjects from scientists working in rheumatology and related fields, as well as proceedings of meetings as supplements to regular issues. Highlights of our 36 years serving Rheumatology include: groundbreaking and provocative editorials such as "Inverting the Pyramid," renowned Pediatric Rheumatology, proceedings of OMERACT and the Canadian Rheumatology Association, Cochrane Musculoskeletal Reviews, and supplements on emerging therapies.